Pharmaceutical Manufacturing Technology Centre

pmtc.ie

The Pharmaceutical Manufacturing Technology Centre (PMTC) is hosted by the University of Limerick with core funding from the Irish government (Enterprise Ireland and the IDA Ireland). Income is supplemented with co-funding from industry and other public sources. PMTC, established in December 2013, is led by an industry steering board with an active research program informed by its industry members. Companies access PMTC to create projects and execute world-beating industry-relevant research in advanced technology solutions to address contemporary manufacturing issues.

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us

Events

Related News

PHARMA TITANS TEAM TO TACKLE COVID-19

Precision Vaccinations | April 14, 2020

news image

Considering the extraordinary humanitarian challenge of ending the ongoing coronavirus pandemic, two leading pharmaceutical companies believe establishing a collaboration is the best tactic for bringing a world-class vaccine. Announced in a joint press release on April 14, 2020, GSK and Sanofi said the ‘global access to COVID-19 vaccines is a priority and are committed to making any vaccine that is developed through the collaboration affordable to the public.’ ‘And through mech...

Read More

VIFOR PHARMA AND CARA THERAPEUTICS ANNOUNCES SIGN LICENSE AGREEMENT FOR IV KORSUVA™* TO TREAT DIALYSIS PATIENTS WITH PRURITUS

Vifor Pharma and Cara Therapeutics, Inc. | October 20, 2020

news image

Vifor Pharma and Cara Therapeutics, Inc. today announced that both companies have signed a license agreement for commercialization of Korsuva (difelikefalin) Injection (“IV Korsuva”) for the treatment of chronic kidney disease-associated pruritus (CKD-aP) in the US dialysis market for non-Fresenius Medical Care clinics under a Cara 60%, Vifor Pharma 40% profit-sharing arrangement. “With an established fully dedicated nephrology sales force in the US, Vifor Pharma is an ideal co...

Read More

Pharmacy Market

VIPERGEN AND LEO PHARMA PARTNER FOR DNA ENCODED LIBRARY (DEL)-BASED DRUG DISCOVERY FOR DERMATOLOGY INDICATIONS

Vipergen | June 20, 2022

news image

Vipergen, a leading provider of small-molecule drug discovery services based on DNA-encoded library technologies, announced a multi-target drug discovery partnership with LEO Pharma focused on novel treatments for dermatology indications. Under the terms of the agreement, Vipergen will apply its high-fidelity DNA-encoded library (DEL) screening technologies, including its new in-living-cell DEL platform, to discover novel small-molecule compounds that bind to selected LEO Pharma t...

Read More

Business Insights

ALNYLAM ANNOUNCES 3-MONTH EXTENSION OF REVIEW PERIOD FOR NEW DRUG APPLICATION FOR VUTRISIRAN

Alnylam Pharmaceuticals, Inc. | April 05, 2022

news image

Alnylam Pharmaceuticals, Inc. the leading RNAi therapeutics company, announced that the U.S. Food and Drug Administration has extended the review timeline of the New Drug Application for vutrisiran, an investigational RNAi therapeutic in development for the treatment of transthyretin-mediated amyloidosis, to allow for the review of newly added information related to the new secondary packaging and labeling facility. Alnylam recently learned that the original third-party secondary packaging and l...

Read More
news image

PHARMA TITANS TEAM TO TACKLE COVID-19

Precision Vaccinations | April 14, 2020

Considering the extraordinary humanitarian challenge of ending the ongoing coronavirus pandemic, two leading pharmaceutical companies believe establishing a collaboration is the best tactic for bringing a world-class vaccine. Announced in a joint press release on April 14, 2020, GSK and Sanofi said the ‘global access to COVID-19 vaccines is a priority and are committed to making any vaccine that is developed through the collaboration affordable to the public.’ ‘And through mech...

Read More
news image

VIFOR PHARMA AND CARA THERAPEUTICS ANNOUNCES SIGN LICENSE AGREEMENT FOR IV KORSUVA™* TO TREAT DIALYSIS PATIENTS WITH PRURITUS

Vifor Pharma and Cara Therapeutics, Inc. | October 20, 2020

Vifor Pharma and Cara Therapeutics, Inc. today announced that both companies have signed a license agreement for commercialization of Korsuva (difelikefalin) Injection (“IV Korsuva”) for the treatment of chronic kidney disease-associated pruritus (CKD-aP) in the US dialysis market for non-Fresenius Medical Care clinics under a Cara 60%, Vifor Pharma 40% profit-sharing arrangement. “With an established fully dedicated nephrology sales force in the US, Vifor Pharma is an ideal co...

Read More
news image

Pharmacy Market

VIPERGEN AND LEO PHARMA PARTNER FOR DNA ENCODED LIBRARY (DEL)-BASED DRUG DISCOVERY FOR DERMATOLOGY INDICATIONS

Vipergen | June 20, 2022

Vipergen, a leading provider of small-molecule drug discovery services based on DNA-encoded library technologies, announced a multi-target drug discovery partnership with LEO Pharma focused on novel treatments for dermatology indications. Under the terms of the agreement, Vipergen will apply its high-fidelity DNA-encoded library (DEL) screening technologies, including its new in-living-cell DEL platform, to discover novel small-molecule compounds that bind to selected LEO Pharma t...

Read More
news image

Business Insights

ALNYLAM ANNOUNCES 3-MONTH EXTENSION OF REVIEW PERIOD FOR NEW DRUG APPLICATION FOR VUTRISIRAN

Alnylam Pharmaceuticals, Inc. | April 05, 2022

Alnylam Pharmaceuticals, Inc. the leading RNAi therapeutics company, announced that the U.S. Food and Drug Administration has extended the review timeline of the New Drug Application for vutrisiran, an investigational RNAi therapeutic in development for the treatment of transthyretin-mediated amyloidosis, to allow for the review of newly added information related to the new secondary packaging and labeling facility. Alnylam recently learned that the original third-party secondary packaging and l...

Read More